The omission of criminal charges for off-label promotion of Serostim is surprising, because the government's earlier plea with Pfizer sent a strong signal that it would criminally charge companies engaged in off-label marketing.
Diana K. Lloyd
Advertisement
Articles by Diana K. Lloyd
Advertisement
Latest Updated Articles
Legal: Shifting Perspective on Off-Label PromotionPublished: January 1st 2006 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
